Convalescence begins

07/05/21 -"We have input the latest numbers from the full Annual Report 2020 on top of the €1.00 dividend per share. This has led to some minor changes here and there."

Executive summary
Conflict of interest

Pages

Language

English

Published on

07/05/21

Download

You may also be interested by these reports :

11/11/25

Deutsche Wohnen

Deutsche Wohnen’s key economic metrics continue to perform well. The communication remains laconic. The qualitative guidance, slightly revised ...

06/11/25

Branicks Group

3Q25 shows Branicks’ financial consolidation is on track & operating performance and net income improved – Guidance slightly changed

05/11/25

Vonovia

Vonovia provides guidance through 2028, indicating accelerated organic growth and an increase in consolidated EBITDA, which will impacts the balance ...

04/11/25

Wereldhave

The CEO’s message is still positive, yet topline growth is landing in Q3 25. Guidance has been clarified, indicating that FFO per share will reach ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue

Klépierre